Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-154 |
Sentence |
denotes |
α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial. |
T2 |
155-166 |
Sentence |
denotes |
BACKGROUND: |
T3 |
167-413 |
Sentence |
denotes |
Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements. |
T4 |
414-424 |
Sentence |
denotes |
OBJECTIVE: |
T5 |
425-593 |
Sentence |
denotes |
Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins. |
T6 |
594-601 |
Sentence |
denotes |
DESIGN: |
T7 |
602-917 |
Sentence |
denotes |
A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h. |
T8 |
918-926 |
Sentence |
denotes |
RESULTS: |
T9 |
927-1149 |
Sentence |
denotes |
Compared with healthy participants, those with MetS had lower (P < 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. |
T10 |
1150-1437 |
Sentence |
denotes |
Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). |
T11 |
1438-1541 |
Sentence |
denotes |
They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: |
T12 |
1542-1655 |
Sentence |
denotes |
2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. |
T13 |
1656-1843 |
Sentence |
denotes |
MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. |
T14 |
1844-2055 |
Sentence |
denotes |
Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein. |
T15 |
2056-2068 |
Sentence |
denotes |
CONCLUSIONS: |
T16 |
2069-2397 |
Sentence |
denotes |
At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. |
T17 |
2398-2478 |
Sentence |
denotes |
These findings support higher dietary α-tocopherol requirements for MetS adults. |
T18 |
2479-2546 |
Sentence |
denotes |
This trial was registered at www.clinicaltrials.gov as NCT01787591. |
T1 |
0-154 |
Sentence |
denotes |
α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial. |
T2 |
155-166 |
Sentence |
denotes |
BACKGROUND: |
T3 |
167-413 |
Sentence |
denotes |
Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements. |
T4 |
414-424 |
Sentence |
denotes |
OBJECTIVE: |
T5 |
425-593 |
Sentence |
denotes |
Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins. |
T6 |
594-601 |
Sentence |
denotes |
DESIGN: |
T7 |
602-917 |
Sentence |
denotes |
A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h. |
T8 |
918-926 |
Sentence |
denotes |
RESULTS: |
T9 |
927-1149 |
Sentence |
denotes |
Compared with healthy participants, those with MetS had lower (P < 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. |
T10 |
1150-1437 |
Sentence |
denotes |
Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). |
T11 |
1438-1541 |
Sentence |
denotes |
They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: |
T12 |
1542-1655 |
Sentence |
denotes |
2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. |
T13 |
1656-1843 |
Sentence |
denotes |
MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. |
T14 |
1844-2055 |
Sentence |
denotes |
Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein. |
T15 |
2056-2068 |
Sentence |
denotes |
CONCLUSIONS: |
T16 |
2069-2397 |
Sentence |
denotes |
At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. |
T17 |
2398-2478 |
Sentence |
denotes |
These findings support higher dietary α-tocopherol requirements for MetS adults. |
T18 |
2479-2546 |
Sentence |
denotes |
This trial was registered at www.clinicaltrials.gov as NCT01787591. |